Histogen Inc

Histogen — Investor Presentation (August 2020)

23 slides from Histogen's investor presentation, Aug 7, 2020

  1. Slide 1: Restoring Function Enhancing Lives

    Restoring Function Enhancing Lives August 7, 2020 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor provisions of the Privat

  3. Slide 3: Developing first-in-class restorative therapeutics

    Histogen is developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function Proprietary hypoxia-generated growth factor technology platform Strong intellectual property portfolio Pipeline focused on multiple thera

  4. Slide 4: Technology Platform Yields Multiple Product Candidate Opportunities

    Technology Platform Yields Multiple Product Candidate Opportunities Growing fibroblast cells under simulated embryonic conditions to induce them to become multipotent with stem cell like properties Spectrum of products created from core technology Human Multipotent Cell Conditioned Media, or CCM con

  5. Slide 5: Robust Pipeline

    Robust Pipeline Preclinical Phase 1 Phase 2 Phase 3 Marketed/Partner CCM Cosmetics HST 001 Hair Growth (HSC) HST 002 Dermal Filler (hECM + Lidocaine) HST 003 Joint Cartilage (hECM) HST 004 Spine (CCM) World Wide Rights China

  6. Slide 6: Large Addressable Markets

    Large Addressable Markets 1 Histogen estimate, U.S. only 2 Histogen market research, U.S. only $3.6 billion ——— Annual spend on hair loss, targeting men aged 30-49 (1) $1.1 billion ——— Annual spend on dermal fillers, 1.2 million patients receiving dermal fillers annually (2) (1) $0.9 billion ——— Ann

  7. Slide 7: HST Hair Growth

    HST 001 Hair Growth A minimally-invasive treatment to promote new hair growth where existing treatments only reduce hair loss

  8. Slide 8: HST Hair Growth Overview

    HST 001 Hair Growth Overview If approved, HST 001, would be the only product to grow new terminal hairs. Current approved products preserve existing hair to reduce overall hair loss Human proteins and growth factors stimulate resting hair follicles to produce new cosmetically-relevant hair Minimally

  9. Slide 9: Three Completed Company-Sponsored Clinical Trials

    Three Completed Company-Sponsored Clinical Trials Pilot in male pattern hair loss Phase 1a in male pattern hair loss Phase 1a in female diffuse hair loss Strong Safety Profile No kidney, liver or bone marrow toxicity No severe adverse events Treatment well tolerated across all subjects Statistically

  10. Slide 10: HST 001 Phase 1b/2a Protocol – Enrollment Complete

    Objective: Optimal dosing of HSC in male pattern hair loss Enrollment Criteria: 36 men, aged 20-55 Male pattern hair loss (Norwood-Hamilton 2A, 3, 3V, 4, 4A) Treatment Regimen: 20 injections of HSC week 0, week 6, week 12 20 injections of placebo (PBS) week 0, week 6, week 12 Endpoints: Adverse even

  11. Slide 11: Phase 1b/2a Study Data Success Criteria

    Study Endpoints: No serious adverse events or indicators of of toxicity Statistically significant improvement in the following parameters based on Canfield Macrophotography analysis of subjects at week 18: Absolute change in total hair count vs. baseline at week 18 (at least 18 more hairs in target

  12. Slide 12: hECM Fillers

    hECM Fillers Human-derived collagen and extracellular matrix dermal fillers for delivering longer-lasting treatment of facial folds and wrinkles

  13. Slide 13: HST Dermal Filler Overview

    HST 002 Dermal Filler Overview If approved, HST 002, would be the only filler providing all-human and naturally produced collagen with dermal matrix proteins hECM filler provides the natural proteins found in young, healthy skin all-human and naturally produced collagen with dermal matrix proteins P

  14. Slide 14: HST Dermal Filler Phase Study Protocol

    HST 002 Dermal Filler Phase 1 Study Protocol Objective: Evaluate human extracellular matrix (hECM) as a dermal filler in direct comparison to Restylane-L in moderate to severe nasolabial folds Enrollment Criteria: 22 patients - men and women; 2 clinical sites Treatment Regimen: hECM filler up to 3 m

  15. Slide 15: hECM Joint Cartilage

    hECM Joint Cartilage Human extracellular matrix regenerates hyaline cartilage for the treatment of articular cartilage defects with a novel malleable scaffold that stimulates the body’s own stem cells.

  16. Slide 16: HST Joint Cartilage Overview

    HST 003 Joint Cartilage Overview If approved, HST 003, would be the only product to regenerate hyaline cartilage which could potentially improve functionality and mobility as well as provide reduction in inflammation, potentially reducing pain. Malleable scaffold applied to full-thickness chondral l

  17. Slide 17: HST Joint Cartilage Preclinical Proof-of-Concept

    HST 003 Joint Cartilage Preclinical Proof-of-Concept Rat model Untreated defects (10) - extensive fibrotic tissue and no articular cartilage at 6 weeks Treated defects (10) - congruent and smooth cartilage regeneration and integration with surrounding cartilage at 6 weeks (O’Driscoll p<0.001) Rabbit

  18. Slide 18: HST Joint Cartilage Phase 1/2 Protocol

    HST 003 Joint Cartilage Phase 1/2 Protocol Objective: Evaluate the safety of hECM paste delivered arthroscopically during microfracture procedure Enrollment Criteria: 15 patients who are candidates for microfracture surgery Recent focal cartilage defects of 2 - 4cm2 in the knee 3 sites: Walter Reed

  19. Slide 19: Summary and Leadership

    Summary and Leadership

  20. Slide 20: Key Clinical Development Milestones

    2020 2020 2021 Q2 Q3 Q4 Q1 Q2 Q3 Q4 HST 001 HST 002 HST 003 HST 004 Key Clinical Development Milestones Initiated Phase 1b/2a study Submit IND Initiate Phase 1 trial Initiate Phase 1/2 study Top-line data readout Submit IND Top-line data readout Top-line data readout (June 2020)

  21. Slide 21: Accomplished Leadership Team

    Accomplished Leadership Team Gail Naughton, Ph.D. Founder/Chief Scientific Officer Martin Latterich, Ph.D. Sr. VP of Technical Operations Richard Pascoe President and CEO Susan Knudson Chief Financial Officer

  22. Slide 22: Positioned for Growth

    Positioned for Growth Validated Technology: Demonstrated pre-clinical/clinical proof of concept with HSC and hECM CCM marketed by Allergan in their SkinMedica TNS A+ brand Strategic Pipeline: Targeting high-value markets with potential first-in-class product candidates Clinical development programs

  23. Slide 23: Restoring Function Enhancing Lives

    Restoring Function Enhancing Lives August 7, 2020

Histogen — Investor Presentation (August 2020) on 6ix